VitalSigns
Return to the Blog Homepage

Issues Management Team

Recent Posts by Issues Management Team

July 17, 2017

0 Comments

Categories: The Week That Was

The Week That Was: Crises in Communications

What may have once seemed like it was ripped from the pages of science fiction was realized last week, when the FDA unanimously voted in support of CAR-T, a pioneering therapy that uses the body’s own immune cells to attack cancer. In contrast to this this giant step forward for patients and providers, the status of “Obamacare” stood steadfastly still after Senate Majority Leader McConnell (KY) again deferred the Chamber’s vote to repeal the Affordable Care Act, pending the return Sen. McCain (AZ) following emergency surgery. With two Republicans—with Sens. Collins (ME) and Paul (KY) refusing to support the bill, McConnell can’t afford to lose a single GOP vote and pass the repeal. Despite the lack of action in Congress, we have plenty of other news for you, so read on for The Week That Was… WHY THE FDA BECAME THE HOTTEST SHOW IN TOWN On Wednesday, an FDA advisory committee voted unanimously to recommend Novartis’ CAR-T therapy for acute lymphoblastic leukemia—moving the U.S. a step closer to having an approved gene therapy. While media coverage of an FDA ad comm usually is proportionate to the novelty of the therapy, magnitude of the breakthrough for patients, and the significance ofContinue Reading

July 10, 2017

0 Comments

Categories: Communications

The Week That Was: Crises in Communications

Although July 4 celebrations have come and gone, fireworks continue in the Martin Shkreli case, in which the defendant continues to mock prosecutors on his Facebook page. While the battle between Pharma Bro and the DOJ rages on, Senate Majority Leader Mitch McConnell has taken a decidedly more collaborative approach, suggesting that the GOP should consider working with Democrats to stabilize the Affordable Care Act in the absence of a successful repeal and replace plan. But we’re not betting on the opposing parties to break out in a group rendition of “kumbaya” anytime soon. And don’t be fooled into thinking that issues are slow this summer—there is a busy week ahead, including a much-anticipated FDA workshop to review the science behind abuse deterrent drug formulations, one of the critical pieces in America’s battle to contain the opioid crisis. No matter whether you were the lone staffer in your office or relaxing on a beach somewhere this past week, we’ve got the run down on the latest healthcare headlines—the good, the bad and the ugly—to help you get you back up to speed. Read on for the latest in The Week That Was… DOES PHARMA MONEY TALK WHEN GIVEN TO KOLS?Continue Reading